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SUMMARY: 22 
Here we present a protocol for the use of pre-existing antibiotic resistance-cassette deletion 23 
constructs as a basis for making deletion mutants in other E. coli strains. Such deletion 24 
mutations can be mobilized and inserted into the corresponding locus of a recipient strain using 25 
P1 bacteriophage transduction.  26 
 27 
ABSTRACT: 28 
A first approach to study the function of an unknown gene in bacteria is to create a knock-out 29 
of this gene. Here, we describe a robust and fast protocol for transferring gene deletion 30 
mutations from one Escherichia coli strain to another by using generalized transduction with 31 
the bacteriophage P1. This method requires that the mutation be selectable (e.g., based on 32 
gene disruptions using antibiotic cassette insertions). Such antibiotic cassettes can be mobilized 33 
from a donor strain and introduced into a recipient strain of interest to quickly and easily 34 
generate a gene deletion mutant. The antibiotic cassette can be designed to include flippase 35 
recognition sites that allow the excision of the cassette by a site-specific recombinase to 36 
produce a clean knock-out with only a ~100-base-pair-long scar sequence in the genome. We 37 
demonstrate the protocol by knocking out the tamA gene encoding an assembly factor involved 38 
in autotransporter biogenesis and test the effect of this knock-out on the biogenesis and 39 
function of two trimeric autotransporter adhesins. Though gene deletion by P1 transduction 40 
has its limitations, the ease and speed of its implementation make it an attractive alternative to 41 
other methods of gene deletion. 42 
 43 
INTRODUCTION:  44 
   
A common first approach to study the function of a gene is to perform knock-out mutagenesis 45 
and observe the resulting phenotype. This is also termed reverse genetics. The bacterium E. coli 46 
has been the workhorse of molecular biology for the last 70 years or so, due to the ease of its 47 
culturing and its amenability to genetic manipulation1. Several methods have been developed 48 
to produce gene deletions in E. coli, including marker exchange mutagenesis2,3 and, more 49 
recently, recombineering using the λ Red or Rac ET systems4-6.  50 
 51 
In a widely used system, coding sequences of individual genes are replaced by an antibiotic 52 
resistance cassette that can later be excised from the chromosome5,7. The coding sequences 53 
are replaced, for instance by a kanamycin (Kan) resistance cassette, which is flanked by flippase 54 
(FLP) recognition target (FRT) sites on either side. The FRT sites are recognized by the 55 
recombinase FLP, which mediates site-specific recombination between the FRT sites leading to 56 
the deletion of the Kan cassette. In this way, a full deletion of a given gene’s coding sequence 57 
can be achieved, leaving behind only a minimal scar sequence of approximately 100 base pairs 58 
(bp) (Figure 1). 59 
 60 
Just over a decade ago, the so-called Keio collection was developed. This is a bacterial library 61 
based on a standard laboratory E. coli K12 strain, where almost all non-essential genes were 62 
individually deleted by λ Red recombination7,8. The clones within this collection each have one 63 
coding sequence replaced with an excisable Kan resistance cassette. The Keio collection has 64 
proven to be a useful tool for many applications9. One such application is the production of 65 
deletion mutants in other E. coli strains. The Kan cassette from a given deletion clone can be 66 
mobilized by generally transducing bacteriophages, such as P110-14. A phage stock prepared 67 
from such a strain can then be used to infect a recipient E. coli strain of interest, where at a low 68 
but reliable frequency the Kan cassette-containing region can be incorporated into the recipient 69 
genome by homologous recombination (Figure 2). Transductants can be selected for the 70 
growth on the Kan-containing medium. Following this, if a removal of the antibiotic resistance 71 
cassette is desired, the FLP recombinase can be supplied to the transductant strain in trans. 72 
After curing the FLP-containing plasmid, which carries an ampicillin (Amp) resistance marker, 73 
Kan and Amp-sensitive clones are screened for, and the correct excision of the wild-type coding 74 
sequence and the Kan cassette are verified by, colony PCR.  75 
 76 
Here, a detailed protocol is presented, describing each of the steps in producing a knock-out E. 77 
coli strain based on the strategy outlined above. As an example, a deletion of the tamA gene is 78 
demonstrated. tamA encodes an outer membrane β-barrel protein that is a part of the 79 
Transport and Assembly Module (TAM), which is involved in the biogenesis of certain 80 
autotransporter proteins and pili15-17. This knock-out strain was then used to examine the effect 81 
of the tamA deletion on the biogenesis of two trimeric autotransporter adhesins (TAAs), the 82 
Yersinia adhesin YadA and the E. coli immunoglobulin (Ig)-binding TAA EibD18,19. 83 
 84 
PROTOCOL: 85 
 86 
1. Strains and Plasmids  87 
 88 
   
1.1. Bacterial strains 89 
 90 
1.1.1. Use the E. coli strains BW251135, JW4179 (BW25113 tamA::kan)7, BL21(DE3)20, and 91 
BL21ΔABCF21. See Table of Materials for further information. 92 
 93 
1.2. Bacteriophages 94 
 95 
1.2.1. Use the phage P1vir for the general transduction. Store the phage as a liquid stock with a 96 
few drops of chloroform (see step 2.2). For more information, see Table of Materials. 97 
 98 
1.3. Plasmids 99 
 100 
1.3.1. Use the following plasmids in this protocol: pCP2022, pIBA2-YadA23, and pEibD1024. As 101 
control plasmids, use pASK-IBA2 and pET22b (see Table of Materials). 102 
 103 
1.4. Growth conditions 104 
 105 
1.4.1. Propagate bacteria in a lysogeny broth (LB) medium25 with vigorous shaking (180 - 200 106 
rpm) at 37 °C or 30 °C in the case of BL21ΔABCF and strains containing pCP20.  107 
 108 
1.4.2. Perform plasmid curing at 42 °C.  109 
 110 
1.4.3. For a solid medium, supplement LB with 1% agar (w/v). 111 
 112 
1.4.4. For top agar, supplement LB with 0.7% agar and 10 mM CaCl2 and autoclave the medium. 113 
Use SOC medium for the recovery after electroporation26.  114 
 115 
1.4.5. Use the following concentrations for antibiotics: 100 μg/mL for Amp and 25 μg/mL for 116 
Kan. 117 
 118 
2. Preparing a Phage Lysate  119 
 120 
2.1. Infection of the donor strain 121 
 122 
2.1.1. Grow the donor strain JW4197 in 5 mL of LB medium supplemented with 10 mM CaCl2 123 
and optionally with Kan (25 µg/mL) to an optical density at 600 nm (OD600) of ~1.0. Measure the 124 
OD600 value using a spectrophotometer.  125 
 126 
2.1.2. Make a dilution of an existing P1 phage stock in the LB medium: recommended dilutions 127 
are between 10-3 to 10-7. 128 
 129 
2.1.3. Mix 200 μL of the bacterial suspension and 100 μL of a given phage dilution in a 15 mL 130 
centrifuge tube or equivalent. Prepare as many tubes as phage dilutions. Incubate the tubes for 131 
20 min at 37 °C without shaking.  132 
   
 133 
2.1.4. Add ~3 mL of molten top agar (~50 °C) supplemented with 10 mM CaCl2 to the tubes, mix 134 
the contents thoroughly by vortexing the tubes shortly, and pour the mixtures onto prewarmed 135 
LB plates to make even layers.  136 
 137 
2.1.5. Incubate the plates overnight at 37 °C.  138 
 139 
2.2. Lysate preparation 140 
 141 
2.2.1. The following day choose a plate with a semi-confluent growth of phage plaques. On a 142 
semi-confluent plate, approximately half the surface area of the plate is clear (Figure 3).  143 
 144 
2.2.2. Scrape the top agar layer from such a plate using an inoculation loop or a similar tool and 145 
place the top agar in a centrifuge tube. Add 1 - 2 mL of LB and a drop of chloroform and vortex 146 
the tube vigorously for ~1 min. Add the chloroform in a fume hood. 147 
 148 
2.2.3. Centrifuge the tube for 15 min at 4,000 x g or faster to pellet the agar and bacterial cells.  149 
 150 
2.2.4. Move the supernatant to a fresh microcentrifuge tube, avoiding carrying over any debris 151 
from the pellet. Add 2 drops of chloroform and store the lysate at 4 - 10 °C. Add chloroform in a 152 
fume hood. Do not freeze the phage lysate as this will result in a significant reduction of the 153 
number of infectious particles. 154 
 155 
2.3. Determining the lysate titer 156 
 157 
2.3.1. Grow BW25113 in LB supplemented with 10 mM CaCl2 at 37 °C till the culture reaches an 158 
OD600 of ~1.0. 159 
 160 
2.3.2. Prepare a dilution series of the phage lysate in LB (e.g., 10-6 - 10-9).  161 
 162 
Note: Be careful to pipet the sample from the top of the lysate to avoid transferring chloroform 163 
to the dilutions. 164 
 165 
2.3.3. Mix 200 μL of the bacterial suspension and 100 μL of a given phage dilution in a 15 mL 166 
centrifuge tube or equivalent. Prepare as many tubes as phage dilutions. Incubate the tubes for 167 
20 min at 37 °C without shaking. 168 
 169 
2.3.4. Add ~3 mL of molten top agar (~50 °C) supplemented with 10 mM CaCl2 to the tubes, mix 170 
the contents thoroughly by vortexing the tubes shortly, and pour the mixture onto prewarmed 171 
LB plates to make even layers.  172 
 173 
2.3.5. Incubate the plates overnight at 37 °C. 174 
 175 
2.3.6. The following day count the number of plaques (clear regions in the bacterial mat) for 176 
   
each plate and calculate the titer of the lysate using the following formula: 177 
 178 
titer (pfu/mL) = 
∑ plaques
∑ dilutions
 × plating factor 179 
 180 
Example: On plates with the dilutions 10-7, 10-8, and 10-9, there are 231, 27, and 2 plaques, 181 
respectively. As 100 μL of each dilution was used for the infection, and because the titer is 182 
expressed as plaque-forming units (pfu)/mL, the plating factor is 10. These numbers are 183 
entered into the formula: 184 
 185 
titer =
231 pfu + 27 pfu + 2 pfu
10−7 + 10−8 + 10−9
× 10mL−1 = 2.34 × 1010pfu/mL 186 
 187 
Thus, the titer is approximately 2 x 1010 infectious phage particles/mL. 188 
 189 
3. P1 Transduction 190 
 191 
3.1. Preparing the recipient cells 192 
 193 
3.1.1. Grow the recipient strain BL21ΔABCF in LB supplemented to an optical density at 600 nm 194 
(OD600) of ~1.0. Use a spectrophotometer to measure the OD600 value.  195 
 196 
3.1.2. Calculate the volume of the phage lysate needed to achieve a multiplicity of infection 197 
(MOI) value of 0.5. To calculate the MOI, estimate the number of bacteria based on the OD600 of 198 
the culture. Assume that an OD600 value of 1.0 corresponds to ~109 cfu/mL. Calculate the 199 
volume required based on the known titer of the lysate. 200 
 201 
Example (based on the titer calculated in the example after step 2.3.6): 202 
 203 
𝑉 =
number of phages
titer of lysate
=
5 × 108 pfu
2.34 × 1010 pfu/mL
= 0.214 mL = 21.4 μL 204 
 205 
3.1.3. Add CaCl2 to the recipient strain culture to 10 mM and mix. Take 1 mL of the culture for 206 
transduction. 207 
 208 
3.2. Performing transduction 209 
 210 
3.2.1. Add the appropriate volume of phage lysate to 1 mL of recipient culture (including CaCl2 211 
at 10 mM) as calculated in step 3.1.2 and mix gently.  212 
 213 
Note: Be careful to pipette the sample from the top of the lysate to avoid transferring 214 
chloroform to the mix. 215 
 216 
3.2.2. Statically incubate the mix for 20 min at 37 °C. 217 
   
 218 
3.2.3. Stop the infection by adding sodium citrate, pH 5.5, to 100 mM.  219 
 220 
3.2.4. Centrifuge the bacteria (5,000 x g for 2 min) and remove the supernatant, then 221 
resuspend them in 1 mL of fresh LB supplemented with 100 mM sodium citrate, pH 5.5. 222 
 223 
3.2.5. Wash the cells 2x more as in step 3.2.4 to ensure the removal of free phages and calcium. 224 
 225 
3.2.6. Resuspend the bacteria in 1 mL of fresh LB supplemented with 100 mM sodium citrate, 226 
pH 5.5. Incubate the bacteria at 30 °C for 1 h with shaking (> 100 rpm).  227 
 228 
3.2.7. Collect the bacteria by centrifugation (5,000 x g for 2 min) and resuspend them in ~100 229 
μL of LB with 100 mM sodium citrate, pH 5.5. 230 
 231 
3.2.8. Spread the bacteria on an LB plate supplemented with Kan at 25 µg/mL and 10 mM 232 
sodium citrate, pH 5.5, and grow the bacteria at 30 °C until colonies appear (~24 h).  233 
 234 
3.3. Selecting the transductants 235 
 236 
3.3.1. Once colonies have grown on the selection plate, restreak them on LB + Kan for single 237 
colonies and grow at 30 °C till single colonies appear.  238 
 239 
4. Excising the Kan cassette  240 
 241 
4.1. The transformation with recombination plasmid 242 
 243 
4.1.1. Make the Kan-resistant BL21ΔABCF strain electrocompetent.  244 
 245 
4.1.1.1. Grow the strain from a single colony in fresh LB (5 mL) supplemented with Kan (25 246 
µg/mL) at 30 °C until the OD600 is ~0.5 - 0.7.  247 
 248 
4.1.1.2. From here on, carry out the following steps at 4 °C or on ice. Centrifuge the bacteria 249 
(5,000 x g for 10 min) and remove the supernatant.  250 
 251 
4.1.1.3. Wash the cell pellet with ice-cold distilled water 2x by repeating the previous 252 
centrifugation step and, finally, resuspend cell pellet in 100 µL of ice-cold 10% glycerol.  253 
  254 
4.1.2. Cool down 1 mm electroporation cuvettes on ice.  255 
 256 
4.1.3. Add 1 pg of plasmid DNA (pCP20) to the cell suspension, mix the suspension gently, and 257 
transfer it to a cooled electroporation cuvette. 258 
 259 
4.1.4. Set the electroporator to 1.8 kV and electroporate the cells.  260 
 261 
   
4.1.5. Rescue transformed cells by adding 1 mL of SOC medium and growing them for 1 h at 30 262 
°C.  263 
 264 
4.1.6. Plate 100 µL of the cells on LB + Amp plates and grow the cells at 30 °C overnight.  265 
 266 
4.2. Induction of the recombination 267 
 268 
4.2.1. Pick single colonies from the LB + Amp plate and inoculate fresh LB omitting all 269 
antibiotics.  270 
 271 
4.2.2. Grow the cells at the non-permissive temperature (43 °C) overnight to induce the 272 
expression of FLP recombinase.  273 
 274 
4.3. Selecting recombinants 275 
 276 
4.3.1. Make serial dilutions and plate 50 µL of a 105-106 dilution on non-selective plates and 277 
grow it overnight at 30 °C.  278 
 279 
5. Verification of the Gene Deletion  280 
 281 
5.1. Verification of the plasmid loss and successful recombination 282 
 283 
5.1.1. Streak single colonies from the plates prepared in step 4.3.1 on LB + Kan, LB + Amp, and 284 
LB plates without antibiotics, in this order. To aid in the streaking, use a colony grid (see 285 
Supplementary File 1). Grow the plates at 30 °C until colonies appear (~24 h).  286 
 287 
5.1.2. Pick 10 - 20 clones that have grown on the non-selective plate but failed to grow on the 288 
selective media for further verification. 289 
 290 
5.2. Additional verification by colony PCR  291 
 292 
5.2.1. Perform a colony PCR with primers flanking the tamA coding sequence (see Table of 293 
Materials). 294 
 295 
5.2.2. Prepare a master PCR mix. The amount of mix needed depends on the number of 296 
colonies to be tested (see the example in Table 1). Mix the reagents on ice, add the polymerase 297 
last.  298 
 299 
5.2.3. Mix the PCR master mix thoroughly, then dispense 20 µL into tubes of a PCR strip. Pick a 300 
small amount of each colony to be screened using a sterile pipette tip and add it to a tube. 301 
Remember to include the original recipient strain for comparison. Optionally, also include the 302 
donor strain.  303 
 304 
5.2.4. Run a PCR reaction (see Table 2 for the program used). 305 
   
 306 
5.2.5. Prepare a 1% agarose gel.  307 
 308 
5.2.5.1. For a 50 mL gel, measure 0.5 g of agarose and add 50 mL of TAE buffer (40 mM Tris, 20 309 
mM acetic acid, and 1 mM EDTA, pH 8.0). Heat the mixture in a microwave oven until all 310 
agarose has dissolved.  311 
 312 
5.2.5.2. Once the agarose has dissolved, cool the solution to approximately 50 °C, and then add 313 
5 μL of DNA staining dye. Mix the solution well and pour it into a gel tray in a casting chamber. 314 
Insert one or more rows of well combs so that there are sufficient wells for all samples, as well 315 
as molecular size markers. Allow the gel to set for 30 min. 316 
 317 
5.2.6. Once the PCR run is complete, add 4 µL of 6x DNA loading dye to each sample. Place the 318 
gel in the electrophoresis chamber and add TAE buffer till the wells are covered. 319 
 320 
5.2.7. Apply 10 - 15 µL from each PCR reaction to a well in the gel. Also add 5 µL of a molecular 321 
size marker. Then, run the gel for 30 min at 75 V. 322 
 323 
5.2.8. Once the run is complete, image the gel using a blue-light imager.  324 
 325 
6. Other Techniques  326 
 327 
6.1. Protein expression 328 
 329 
Note: The expression of test proteins (YadA and EibD) has been described in detail 330 
elsewhere23,24. This is a brief summary of the main steps.  331 
 332 
6.1.1. Transform BL21ΔABCF ΔtamA with the necessary plasmids (pIBA2-YadA and pEibD10 and 333 
the corresponding control plasmids) and select for transformants on LB + Amp.  334 
 335 
6.1.2. For the protein expression, inoculate 100 mL of LB medium + Amp with 1 mL of an 336 
overnight culture of transformed bacteria and grow these at 30 °C until mid-log phase, at which 337 
time, induce the protein production with either anhydrotetracycline (at 100 ng/mL) or isopropyl 338 
thiogalactoside (at 0.5 mM).  339 
 340 
6.1.3. After 2 h of induction at 30 °C, measure the turbidity of the cultures and collect a number 341 
of cells corresponding to 50 mL at OD600 = 1.0 by centrifuging the cultures for 15 min at 4,000 x 342 
g. Wash the pellet 1x with 10 mM HEPES, pH 7.4, and then either store it at -20 °C or process it 343 
further as in step 6.2. 344 
 345 
6.2. Outer membrane extraction 346 
 347 
Note: Outer membrane extraction is performed as described in detail by Leo et al.27. The main 348 
steps are summarized below.  349 
   
 350 
6.2.1. Resuspend the cell pellet in 1 mL of 10 mM HEPES, pH 7.4, supplemented with 10 mM 351 
MgCl2 and MnCl2, lysozyme (0.1 mg/mL), and a pinch of DNase I.  352 
 353 
6.2.2. Lyse the cells (e.g., using a bead beater).  354 
 355 
6.2.3. Centrifuge the cells shortly (2 min at 15,600 x g) to remove cell debris and move the 356 
supernatant to a fresh tube.  357 
 358 
6.2.4. Centrifuge the cells for 30 min at 16,000 x g, after which, resuspend the pellet in 400 μL 359 
of 1% N-lauroyl sarcosine in 10 mM HEPES, pH 7.4.  360 
 361 
6.2.5. Incubate the cells with agitation for 30 min at room temperature, after which, centrifuge 362 
them for 30 min as above.  363 
 364 
6.2.6. Wash the translucent pellet 1x with 200 μL of 10 mM HEPES, pH 7.4, and then resuspend 365 
it in 30 μL of 10 mM HEPES and add 10 μL of 4x SDS-PAGE sample buffer. 366 
 367 
6.3. Activity assays 368 
 369 
Note: Perform SDS-PAGE and activity assays for YadA and EibD as described28. The main steps 370 
are summarized below. 371 
 372 
6.3.1. SDS-PAGE 373 
 374 
6.3.1.1. Heat the samples at 50 °C for 5 min before loading them onto a polyacrylamide gel, to 375 
avoid denaturing the proteins.  376 
 377 
6.3.1.2. After the separation in SDS-PAGE, transfer the proteins to a polyvinylidene difluoride 378 
(PVDF) membrane.  379 
 380 
6.3.1.3. After the transfer, block the membrane with 2% skimmed-milk powder in PBS. 381 
 382 
6.3.2. YadA-collagen far-western blot 383 
 384 
6.3.2.1. After the blocking, add bovine collagen type I diluted in blocking buffer to a 385 
concentration of 10 μg/mL and incubate the membrane for 1 h.  386 
 387 
6.3.2.2. Wash the membrane 2x with PBS + 0.05% Tween20 (PBS-T).  388 
 389 
6.3.2.3. Add the primary antibody (monoclonal anti-collagen COL-1) to the membrane, diluted 390 
1:2,000 in blocking buffer.  391 
 392 
6.3.2.4. After incubating the membrane for 1 h, wash 2x as mentioned in step 6.3.2.2 and then 393 
   
add the secondary antibody [goat anti-mouse IgG-horseradish peroxidase (HRP) conjugate], 394 
diluted 1:10,000 in blocking buffer.  395 
 396 
6.3.2.5. Incubate the membrane for 1 h, then wash it 2x with PBS-T. Add an enhanced 397 
chemiluminescent substrate to the membrane according to the manufacturer’s instructions and 398 
detect the band using a CCD camera. 399 
 400 
6.3.3. EibD-IgG binding assay 401 
 402 
6.3.3.1. After the blocking, add a secondary antibody (goat anti-rabbit HRP), diluted 1:2,000 in 403 
blocking buffer.  404 
 405 
6.3.3.2. Incubate the membrane for 1 h, then wash it 2x with PBS. Perform chemiluminescent 406 
detection as mentioned in step 6.3.2.5. 407 
 408 
REPRESENTATIVE RESULTS:  409 
 410 
Generation of a tamA Knock-out of BL21ΔABCF: 411 
The strategy outlined above has previously been used to produce a derivative strain of 412 
BL21(DE3), a standard laboratory strain used for protein production, which is optimized for 413 
outer membrane protein production and called BL21ΔABCF21. This strain lacks four genes 414 
coding for abundant outer membrane proteins and, consequently, is able to produce more 415 
heterologously expressed outer membrane proteins than the wild-type strain. To test whether 416 
the TAM is involved in TAA biogenesis, the tamA gene was deleted in this background.  417 
 418 
A P1 lysate was prepared from the Keio collection strain JW4179, where the tamA gene 419 
(previously called yftM) coding sequence is replaced by a Kan resistance cassette. Then, a 420 
transduction experiment was performed with BL21ΔABCF as the recipient strain. Several Kan-421 
resistant colonies were obtained, after which two were chosen for the excision of the Kan 422 
cassette. The plasmid pCP20, encoding the FLP recombinase, was introduced into these clones 423 
and, subsequently, cured by growing at 43 °C in the absence of an antibiotic selection. A 424 
number of clones were screened for sensitivity to both Amp (which is a marker of pCP20) and 425 
Kan, and several clones sensitive to both were obtained. These clones were verified by colony 426 
PCR using primers flanking the tamA coding sequence and found that the tamA gene had 427 
successfully been deleted (Figure 4). 428 
 429 
TamA’s Role in TAA Biogenesis: 430 
TamA has been shown to be involved in the biogenesis of some classical autotransporters16 and 431 
the inverse autotransporter intimin15. To test whether TamA is important for the biogenesis of 432 
TAAs, BL21ΔABCF ΔtamA was transformed with plasmids encoding two test proteins, the 433 
Yersinia adhesin YadA and the E. coli immunoglobulin-binding protein EibD. These proteins are 434 
known to express well in E. coli and have been used as models for TAA biogenesis in earlier 435 
studies23,28. 436 
 437 
   
After inducing protein production, the outer membrane fractions of the expression cultures 438 
were isolated and analyzed by SDS-PAGE. The samples were not boiled to demonstrate 439 
trimerization of the proteins. The trimers run at sizes above 100 kDa, whereas the monomers 440 
have expected sizes of 45 kDa (YadA) and 51 kDa (EibD). No major differences were observed 441 
between the expression levels in BL21ΔABCF and BL21ΔABCF ΔtamA, although YadA seems to 442 
be produced at somewhat lower levels in the ΔtamA strain (Figure 5A). However, the opposite 443 
appears to be the case for EibD.  444 
 445 
To examine whether the lack of TamA might influence the correct folding or transport of the 446 
proteins, their ability to bind to ligands was tested. For YadA, this was accomplished by a 447 
collagen far-western blot (Figure 5B). YadA, in both strains, bound collagen at a similar level, 448 
demonstrating that the protein is correctly folded and functional. Similarly, immunoglobulin G-449 
binding activities of EibD in the two strains correlated with the expression level (Figure 4C). 450 
These results demonstrate that the deletion of tamA does not have a significant effect on TAA 451 
biogenesis, at least not for these two model TAAs.  452 
 453 
FIGURE AND TABLE LEGENDS:  454 
 455 
Figure 1: Generation of knock-outs with excisable antibiotic cassettes. For producing the gene 456 
knock-outs, a gene of interest (Gene B in this example) is replaced by a Kan resistance cassette 457 
flanked by FRT sites. The FRT-Kan cassette, in turn, is flanked by short (~50 bp) stretches of 458 
sequence homologous to the upstream and downstream regions of the Gene B. The coding 459 
sequence of Gene B is exchanged for the FRT-Kan cassette by λ Red recombination. Once this is 460 
accomplished, the Kan cassette itself can be removed by introducing the FLP recombinase, 461 
which will mediate a site-specific recombination between the FRT sites. This excises the Kan 462 
cassette, leaving a minimal (~100 bp) scar sequence in the B locus. For full details, see Baba et 463 
al.7. 464 
 465 
Figure 2: Gene deletion by P1 transduction. The donor strain (beige) carries a Kan cassette that 466 
has replaced the gene of interest (yellow) on the chromosome (blue). The donor is infected 467 
with P1 bacteriophage. The phage multiplies in the donor strain, producing a large number of 468 
progenies. Most are wild-type (red genome), but a fraction are transducing phages that have 469 
incorporated a portion of the donor strain chromosome rather than phage DNA (blue genome). 470 
A proportion of these will contain the Kan cassette (yellow genome). Eventually, the infected 471 
host cell lyses and releases the phages into the medium. These are used to prepare a lysate. In 472 
the transduction experiment, the recipient strain (light blue) is infected with the lysate 473 
prepared from the donor strain. In a minority of cases, the recipient is infected by a transducing 474 
phage carrying the Kan cassette (shown here). If the regions adjacent to the Kan cassette 475 
undergo homologous recombination, the Kan cassette is incorporated into the recipient 476 
chromosome replacing the endogenous allele, resulting in Kan-resistant clones that can be 477 
selected for. The addition of FLP recombinase on a curable plasmid excises the Kan cassette, 478 
leaving only a short scar sequence (shown here in yellow), which reverts the clone to the Kan-479 
sensitive phenotype. 480 
 481 
   
Figure 3: Examples of plates after a P1 infection. (A) This panel shows a plate with individual 482 
plaques. (B) This panel shows a semi-confluent plate. (C) This panel shows an over-infected 483 
plate, where almost all the bacteria have been lysed by phage. Some resistant colonies have 484 
grown out of the top agar layer. 485 
 486 
Figure 4: Deletion of the tamA coding sequence. The tamA::kan deletion allele was introduced 487 
into the strain BL21ΔABCF by P1 transduction. After the excision of the Kan cassette, a scar 488 
sequence (~100 bp) is all that remains at the tamA locus. This was verified by PCR, using 489 
primers flanking the deletion site. In BL21ΔABCF and its parent strain, BL21(DE3), the PCR gives 490 
a product the length of the tamA coding sequence (the expected size is 1.7 kilobase pairs). In 491 
BL21ΔABCF, where the Kan cassette has been excised, the product corresponds to the expected 492 
scar sequence (145 bp). 493 
 494 
Figure 5: Expression of TAAs by a tamA deletion strain. (A) This panel shows the SDS-PAGE of 495 
outer membranes prepared from cells expressing TAAs (YadA or EibD) and vector controls 496 
(pIBA2 and pET22). The strains are BL21ΔABCF and its derivative strain lacking TamA (ΔtamA). 497 
(B) This panel shows a collagen far-western blot of YadA samples. The YadA samples and pIBA2 498 
controls from panel A were transferred to a PVDF membrane and incubated with collagen type 499 
I. They were then probed with an anti-collagen antibody and detected by ECL. (C) This panel 500 
shows an antibody binding assay for EibD samples. The EibD samples and pET22 controls from 501 
panel A were transferred to a PVDF membrane and incubated with an HRP-conjugated 502 
secondary antibody and then detected by ECL. 503 
 504 
Table 1: Colony PCR master mix. The amount of mix depends on the number of colonies to be 505 
screened. In addition, prepare a control reaction (original recipient strain). For instance, if 506 
screening five clones, six reactions are needed, including the control. It is worth preparing an 507 
extra reaction to make sure there is enough PCR mix for all samples (repeated pipetting 508 
amplifies small pipetting errors). In this example, prepare a 7x mix (5 colonies, 1 control, and 1 509 
extra reaction). 510 
 511 
Table 2: Colony PCR program. 512 
 513 
Supplementary File 1: An example of colony grid.  514 
 515 
DISCUSSION: 516 
P1 transduction is a fast, robust, and reliable method for generating gene deletions in E. coli. 517 
This is demonstrated here by transducing a tamA deletion mutant from a Keio donor strain to a 518 
BL21-derived recipient. The major stages in the transduction process are the production of the 519 
transducing lysate, the transduction itself, the excision of the Kan resistance cassette, and the 520 
verification of the knock-out by PCR. In total, the process takes approximately 1 week and 521 
requires no molecular biology methods to be used, apart from the final PCR for the verification. 522 
Thus, P1 transduction can compete in expended effort and time with λ Red recombination and 523 
is much faster than traditional marker exchange mutagenesis.  524 
 525 
   
The presented protocol is very robust and allows for modifications of many of the steps. There 526 
are, however, a few critical parameters. For P1 infections, it is necessary to add calcium ions to 527 
the medium. Calcium is needed for the adsorption of the phage to the bacteria, and failure to 528 
add sufficient calcium to the medium will significantly reduce the efficiency of the infection. 529 
Some bacterial strains such as BL21ΔABCF tend to aggregate in the presence of CaCl221. In such 530 
cases, the bacteria can be grown without CaCl2, which can be added to the suspension shortly 531 
before the infection. However, for more conventional strains, 10 mM CaCl2 can be included in 532 
the growth medium from the beginning.  533 
 534 
Conversely, it is important to remove the free calcium from the medium after the transduction. 535 
Citrate is a chelator of calcium ions, and because these are needed for the adsorption of P1 to 536 
host cells, removing the free calcium from the medium prevents further infections. If the 537 
calcium is not removed, the phages will infect further cells throughout the culture, at best 538 
reducing the efficiency of the transduction and at worst lysing the whole culture, including the 539 
transductants. 540 
 541 
Another critical step is culturing bacteria carrying the plasmid pCP20. pCP20 is a conditionally 542 
replicating plasmid that does not replicate at temperatures of 37 °C or higher; thus, to establish 543 
the plasmid in the cells, incubations with this plasmid must be performed at 30 °C (or lower), a 544 
temperature permissive for the replication of pCP20. For curing pCP20, a high temperature (43 545 
°C) is used. Some strains do not grow well at this temperature; in such cases, 37 °C should 546 
suffice, although the plasmid curing will be somewhat less efficient at this temperature. 547 
 548 
When plating bacteria to test for antibiotic sensitivity, the order of plate streaking is important. 549 
The protocol calls for clones to be streaked first on antibiotic-containing plates and finally on 550 
non-selective medium. In this way, the investigator can be sure that any lack of growth on the 551 
selective media will be due to antibiotic sensitivity and rather than to a potential lack of 552 
material transferred on the plates. Following the protocol, no growth on the LB + Kan plate 553 
validates the excision of the Kan resistance cassette; no growth on the LB + Amp plate validates 554 
the loss of the recombination plasmid pCP20; strains growing on the LB plate (which did not 555 
grow in the same streaking experiment on the selection plates) will contain the positive 556 
recombinants. 557 
 558 
Most of the other steps allow for considerable leeway. In the protocol as presented, 559 
BL21ΔABCF is cultured at 30 °C, as this strain does not grow well at 37 °C. However, E. coli 560 
strains without growth defects may be cultured at 37 °C (except when transformed with 561 
pCP20).  562 
 563 
The number of bacteria used for infections can be varied to some extent. The relationship 564 
between OD600 and a viable count is roughly linear between an OD600 value of 0.1 and 1.0, 565 
where the former corresponds to approximately 108 cfu/mL and the latter to ~109 cfu/mL. 566 
However, this relationship may vary to some extent depending on the strain in question, the 567 
growth medium, and other factors. It is recommended that the relationship between OD600 and 568 
the viable count should be established for each laboratory and strain, particularly for calculating 569 
   
MOI values. The number of bacteria used in infection experiments is not particularly critical, 570 
and 109 cfu/mL represents the early stationary phase, which is a reasonable compromise 571 
between cell density and the proportion of viable cells in the culture. If a lower number of 572 
viable bacteria are used for transduction, the number of phages simply needs to be adjusted 573 
accordingly. The MOI itself can also be varied to some extent. The protocol calls for an MOI 574 
value of 0.5, although anything between 0.1 and 0.5 should result in a good efficiency. At an 575 
MOI of 0.5, the ratio of phages to bacteria is 1:2 (i.e., half the number of phages compared to 576 
the number of bacteria). In the example in the protocol, the OD600 of the culture is 1.0, and 1 577 
mL of the culture is used for the transduction; thus, the number of phages required is 5 x 108. 578 
An MOI value of 0.5 gives a high level of infection but reduces the number of bacteria that are 579 
doubly infected, which would reduce the efficiency of the transduction as the wild-type 580 
(infectious) phages far outnumber the transducing phages. A double infection with a 581 
transducing phage and an infectious phage would lead to cell lysis, thus eliminating this 582 
transductant from the pool of survivors. Therefore, an MOI of 0.5 should not be exceeded. 583 
 584 
The protocol also allows for some shortcuts. Rather than preparing lysates from plates, some 585 
authors advocate preparing phage lysates in liquid medium29. This can save time as an 586 
overnight incubation step is not needed. Similarly, titrating the phage lysate might not be 587 
necessary. As noted above, the M.O.I. is not very critical, and reasonable efficiency can be 588 
achieved by simply assuming a titer of 1010 pfu/mL for a standard lysate.  589 
 590 
Despite the ease of the technique, P1 transduction is not universally applicable, and several 591 
conditions must be met for it to be useful. Firstly, a donor strain with a selectable knock-out 592 
allele must be available. This is usually accomplished by using a deletion where an antibiotic 593 
resistance cassette has replaced the gene of interest. The Keio collection is particularly useful in 594 
this regard, as it offers a ready-to-use library of antibiotic cassette-based gene knock-outs 595 
covering almost all non-essential genes in E. coli K12. This collection is particularly useful for 596 
knocking out conserved genes found in most E. coli strains (i.e., constituents of the E. coli core 597 
genome). For less common genes, such as virulence factors of pathogenic E. coli strains or rare 598 
metabolic pathway genes, the mutation may need to be created de novo. In such cases, P1 599 
transduction may well not be the method of choice. In addition to essential genes, genes that 600 
are required for P1 infection, such as galU, mutations of which lead to P1 resistance30, are poor 601 
targets for a deletion by P1 transduction. Another note when using the Keio collection, 602 
specifically, is that a few strains carry a duplication of the targeted gene, where only one copy 603 
was disrupted by the Kan resistance cassette8. In such cases, the gene of interest may be 604 
essential; investigators are recommended to check updated annotations for such genes8. 605 
However, given these restraints, P1 transduction allows the deletion of most genes in 606 
laboratory E. coli strains. For example, the differences between BW25113 and BL21(DE3) are 607 
small and affect only a handful of protein-coding genes31.  608 
 609 
Secondly, it is important to emphasize that the recipient strain must be capable of a 610 
homologous recombination for the transduction to work. A strain lacking the recombinase RecA 611 
can, therefore, not be modified by this method. This excludes all standard cloning strains, such 612 
as DH5α, HB101, TOP10, and XL-1 Blue. RecA can mediate recombinations between identical 613 
   
stretches as short as 8 bp; however, a longer region of high similarity will increase the 614 
probability of recombination significantly32,33. Another problem, particularly with clinical E. coli 615 
strains, is that long O-antigen chains may mask the receptor for P1, which lies in the core 616 
oligosaccharide of lipopolysaccharide34. In addition to these requirements for the recipient 617 
strain, the P1 strain used for transduction should be a vir mutant; this mutation is required for a 618 
full lytic infection35. 619 
  620 
A third caveat of P1 transduction is that the gene to be knocked out should reside in a region 621 
with high similarity in the flanking regions between the donor and recipient strains. If there is a 622 
lack of synteny between the strains, the replacement of the target gene coding sequence with 623 
the Kan cassette may well fail, due to differences in the content of the flanking regions. 624 
Therefore, before embarking on P1-mediated gene deletion, investigators should check the 625 
sequences of the donor and recipient strains to make sure the flanking sequences are 626 
homologous. Of course, this is only possible if the strains have been sequenced. In the case of 627 
strains with an unknown sequence, P1 transduction may either fail or cause other problems, 628 
such as a gene conversion in the flanking regions. P1 can transduce approximately 90 kilobase 629 
pairs of DNA; if there are differences in the gene content in the regions around the target gene 630 
(e.g., small deletions or insertions), it is likely that these will revert to the donor sequence. This 631 
might have unintended consequences on the phenotype of the recipient strain. Therefore, 632 
where possible, the sequences of the donor and recipient around the gene of interest should 633 
always be compared prior to P1 transduction. 634 
 635 
In conclusion, P1 transduction is a rapid way of transferring a specific gene knock-out to a 636 
number of strains once the initial knock-out mutation has been generated. Though the 637 
technique has its limitations, the ease and speed of its implementation make it an attractive 638 
alternative to other methods of gene deletion. P1 only infects E. coli, which normally restricts 639 
its use to this species. However, some variants of P1 have been developed that have a broader 640 
host range and can infect other species within the family Enterobacteriaceae, and even some 641 
other γ-proteobacterial species, albeit at reduced efficiency36,37. Even the transduction of 642 
cloned DNA from E. coli to Myxococcus xanthus, a δ-proteobacterium, has been reported38. In 643 
future experiments, these variants could be augmented with the vir mutation to broaden the 644 
range of recipient strains used in antibiotic cassette-based gene deletion by general 645 
transduction. 646 
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